Faster-acting insulin aspart
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT03215498 | Jul → Nov 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02933853 | Oct 2016 → Dec 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02568280 | Oct 2015 → Apr 2016 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02131246 | May → Jul 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02035371 | Jan → Jul 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02033239 | Jan → Jun 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01992588 | Nov 2013 → Mar 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01934712 | Aug 2013 → Jan 2014 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01924637 | Aug → Nov 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01618188 | Jun → Sep 2012 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01469143 | Nov 2011 → Jan 2012 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01296438 | Feb → Mar 2011 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01121276 | Apr → Sep 2010 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 36 trials · 3 met primary | ||||||
| Phase 3 | NCT03268005 | Sep 2017 → Jan 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02825251 | Jul 2016 → Jun 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02670915 | May 2016 → Feb 2018 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02500706 | May 2016 → Jul 2017 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT01850615 | Sep 2013 → Nov 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
| Phase 3 | NCT01819129 | Sep 2013 → Jan 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
Press releases naming this drug 15 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Faster-acting insulin aspart | “The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with...” NCT02033239 ↗ |
| Known as | fast-acting insulin aspart | “The aim of this study was to investigate the association between baseline characteristics [HbA1c and body mass index (BMI)] and the effect of mealtime fast-acting insulin...” PMID 30547388 ↗ Dec 20187“A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without...” PMID 32209647 ↗ Mar 2020 “Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation aiming to mimic the fast endogenous prandial insulin release more closely than...” PMID 28205039 ↗ May 2017 “Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).” PMID 28345792 ↗ Jul 2017 “AIM: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp).” PMID 29493118 ↗ Mar 2018 “AIMS: To investigate the pharmacokinetic/pharmacodynamic properties of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in people with type 2 diabetes (T2D).” PMID 31069935 ↗ Jun 2019 “Ultra-fast-acting insulins, such as fast-acting insulin aspart (faster aspart), have pharmacokinetic properties” PMID 28918652 ↗ Sep 2017 “Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp).” PMID 30402720 ↗ May 2019 |
| Known as | faster aspart | “OBJECTIVE: To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without...” PMID 32209647 ↗ Mar 202011“AIM: To evaluate the efficacy and safety of mealtime or post-meal fast-acting insulin aspart (faster aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin...” PMID 30259644 ↗ Oct 2018 “Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation aiming to mimic the fast endogenous prandial insulin release more closely than...” PMID 28205039 ↗ May 2017 “AIM: To evaluate the pharmacological characteristics of faster-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp) during continuous subcutaneous insulin...” PMID 27709762 ↗ Nov 2016 “AIM: To investigate the mechanisms behind the lower postprandial glucose (PPG) concentrations achieved with fast-acting insulin aspart (faster aspart) than with insulin aspart (IAsp).” PMID 29493118 ↗ Mar 2018 “AIMS: To investigate the pharmacokinetic/pharmacodynamic properties of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in people with type 2 diabetes (T2D).” PMID 31069935 ↗ Jun 2019 “BACKGROUND: Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with additional excipients (L-arginine and niacinamide).” PMID 28165180 ↗ Feb 2017 “AIM: To confirm glycaemic control superiority of mealtime fast-acting insulin aspart (faster aspart) in a basal-bolus (BB) regimen vs basal-only insulin.” PMID 28345792 ↗ Jul 2017 “Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.” PMID 28483786 ↗ May 2017 “Ultra-fast-acting insulins, such as fast-acting insulin aspart (faster aspart), have pharmacokinetic properties” PMID 28918652 ↗ Sep 2017 “Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting formulation of insulin aspart (IAsp).” PMID 30402720 ↗ May 2019 |
| Known as | FIAsp | “The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body)...” NCT01924637 ↗6“This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) properties of FIAsp (faster-acting...” NCT02035371 ↗ “The aim of the trial is to investigate efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult subjects...” NCT01850615 ↗ “The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with...” NCT02033239 ↗ “properties of FIAsp (faster-acting insulin aspart) and the currently marketed insulin aspart (NovoRapid®)” NCT01934712 ↗ “FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®)” NCT01992588 ↗ “Faster-acting insulin aspart (FIAsp)” NCT01819129 ↗ |
| Route | Subcutaneous | “0.2 U/kg body weight injected subcutaneously (under the skin)” NCT01121276 ↗ |